Dermata Therapeutics, Inc.
DRMA
$0.6758
-$0.0183-2.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.77M | 4.31M | 4.39M | 4.47M | 4.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.65M | 12.51M | 11.53M | 10.12M | 8.97M |
| Operating Income | -11.65M | -12.51M | -11.53M | -10.12M | -8.97M |
| Income Before Tax | -11.46M | -12.29M | -11.27M | -9.82M | -8.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.46 | -12.29 | -11.27 | -9.82 | -8.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.46M | -12.29M | -11.27M | -9.82M | -8.69M |
| EBIT | -11.65M | -12.51M | -11.53M | -10.12M | -8.97M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -7.59 | -14.20 | -19.96 | -26.01 | -31.26 |
| Normalized Basic EPS | -4.74 | -8.87 | -12.47 | -16.25 | -19.54 |
| EPS Diluted | -7.59 | -14.20 | -19.96 | -26.01 | -31.26 |
| Normalized Diluted EPS | -4.74 | -8.87 | -12.47 | -16.25 | -19.54 |
| Average Basic Shares Outstanding | 10.82M | 6.11M | 2.99M | 1.65M | 1.16M |
| Average Diluted Shares Outstanding | 10.82M | 6.11M | 2.99M | 1.65M | 1.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |